Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your genes guide prostate cancer care? new study investigates

NCT ID NCT04254133

Knowledge-focused Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looks at inherited gene changes (like BRCA) in men with prostate cancer to understand how common they are and how they affect treatment. Researchers will collect saliva samples and health information from 1,360 men in Washington state. The goal is to improve cancer care and help family members know their own cancer risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,360 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2018

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients living in Washington State with a new diagnosis of prostate cancer and first degree relatives of patients with prostate cancer

Ages

35 to 89 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Case Ascertainment \[Cancer Surveillance System (CSS)/Washington State Cancer Registry (WSCR)\]: * Signed informed consent form providing agreement for germline genetic and molecular testing, use release of health and research information; and * Male aged 35 to 89 years; and * Diagnosis of prostate cancer; and * Resident of Washington state at diagnosis; and * Willing to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history; and * Willing and able to provide a saliva sample; and * United States (U.S.) mailing address. Inclusion Criteria: Case Ascertainment \[UW Medical Center (UWMC)/UW Harborview Medical Center (UWHMC)\]: * Signed informed consent form providing agreement for germline genetic and molecular testing, use release of health and research information; and * Male aged 35 to 89 years; and * Diagnosis of prostate cancer; and * Self-identifies as Black, African American, or African; and * Receiving care at UWMC or UWHMC; and * Willing and able to provide a saliva sample; and * Able to provide either a U.S. mailing address or Email address or Phone number. Inclusion Criteria: Family Recruitment * Signed informed consent form providing agreement for germline genetic and molecular testing, use and release of health and research information; and * Males aged 35 to 89 years; and * Willingness to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history; and * Willing and able to provide a saliva sample; and * U.S. mailing address Exclusion Criteria: Case Ascertainment * Unable to provide informed consent, e.g., decisional impairment * Prior bone marrow transplant * Currently under treatment for a hematologic malignancy * Study team members Exclusion Criteria: Family Recruitment * Unable to provide informed consent, e.g., decisional impairment * Prior bone marrow transplant * Currently under treatment for a hematologic malignancy * Study team members

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.